Law360, New York (March 07, 2012, 5:19 PM ET) -- Amgen Inc. asked the U.S. Supreme Court last week to review the Ninth Circuit's refusal to decertify a class of shareholders who allege Amgen misled investors about two top-selling anemia drugs, saying the investors did not prove the alleged misstatements were material.
The biotechnology company said in its March 1 petition that the Ninth Circuit was wrong to rule that the pension fund investors only needed to plausibly allege — not prove — that the company's public statements had been false and material in order to...
Amgen Seeks High Court Review Of Investor Class Cert.
To view the full article, take a free trial now.
